Axinn Advised Thermo Fisher on $1.85B Acquisition of PeproTech, Inc.
January 5, 2022
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its approximately $1.85 billion acquisition of PeproTech, Inc., a leading developer and manufacturer of recombinant proteins. The deal closed on December 30, 2021. The Axinn antitrust team included partners John Harkrider and Mark Alexander, who were assisted by Craig Minerva, Tasneem Chowdhury, Megan Walden, and Kyle Sherwood.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
GCR Live: Law Leaders Global 2025
Speaking Engagement
Antitrust
Evidence for Trial Lawyers: Motions, Introducing Evidence, and Objections
Speaking Engagement
Intellectual Property
NYC Bar Trade Secrets Symposium 2024: Navigating the Law of Trade Secrets and Restrictive Covenants
Speaking Engagement
Intellectual Property
Stakeholders 24th Annual CYOC Career Development Conference
Sponsorship
IAM Connect Patent Policy and Litigation Conference 2024
Speaking Engagement
Intellectual Property
CompLaw 33rd Annual Advanced EU Brussels Conference
Speaking Engagement
Jason Murata Named a Profiles in Diversity Journal Diverse Lawyers Making a Difference Award Winner
Awards & Recognitions
Intellectual Property
AIC General Counsel Day 2024
Speaking Engagement
Antitrust
ALM General Counsel Conference East 2024
Speaking Engagement
Antitrust
Global M&A Antitrust Outlook: Trends Shaping Enforcement Strategies
Speaking Engagement
Antitrust